Effects of calcitriol pulse therapy per os in CAPD patients.
Pulse calcitriol therapy (IV or per os) has been efficacious in hemodialysis (HD) patients to inhibit parathyroid hormone (PTH) levels, but there are very poor data for continuous ambulatory peritoneal dialysis (CAPD) patients. For this reason, we used calcitriol (C) per os (0.75-1.5 micrograms three times weekly) in 19/54 patients who had PTH > 150 pg/mL (on peritoneal dialytic treatment for 6-114 months, weekly KT/V 2.01 +/- 0.43); 16% were in therapy with calcium (Ca) carbonate, 26% with calcium acetate alone, and 58% with calcium acetate associated with magnesium (Mg) carbonate and reduction of dialysate Ca (CaD) and dialysate Mg (MgD), respectively, to 1.25 and 0.25 mmol/L. In 5 patients (26%), a further reduction of CaD to 0 mmol/L has been necessary, and 3 patients must be considered nonresponders after three months of treatment. In conclusion, the use of calcitriol as pulse therapy (three times weekly), and at low doses, allows a good control of secondary hyperparathyroidism in 85% of patients who are using phosphate binders without aluminum, if CaD is reduced in some patients to 1.25 or even to 0 mmol/L.
Scanziani
R
R
Renal Unit, Ospedale di Desio, Milan, Italy.
Dozio
B
B
Bonforte
G
G
Surian
M
M
D000085:Acetates / Q000627:therapeutic use; D019342:Acetic Acid; D000284:Administration, Oral; D000328:Adult; D000368:Aged; D002117:Calcitriol / Q000008:administration & dosage*; D002119:Calcium Carbonate / Q000627:therapeutic use; D006801:Humans; D006962:Hyperparathyroidism, Secondary / Q000188:drug therapy / Q000209:etiology; D008274:Magnesium / Q000627:therapeutic use; D008875:Middle Aged; D010281:Parathyroid Hormone / Q000097:blood; D010531:Peritoneal Dialysis, Continuous Ambulatory / Q000009:adverse effects
D000085:Acetates; D010281:Parathyroid Hormone; C005479:magnesium carbonate; D002117:Calcitriol; D002119:Calcium Carbonate; D008274:Magnesium; D019342:Acetic Acid